SixPeaks Bio AG Unveils Pipeline of Therapies for Healthy Weight Loss

SixPeaks Bio AG unveils a pipeline of therapies for healthy weight loss, including a best-in-class dual-specific antibody targeting activin type IIA and B receptors. The company secures $30 million in Series A financing and a strategic collaboration with AstraZeneca, potentially providing up to $80 million over the next two years.